Latest Period
n/a
Security Snapshot
GYRE THERAPEUTICS INC - COM Institutional Ownership
CUSIP: 403783103
13F Institutional Holders and Ownership History from Q4 2023 to Q4 2025
Institutions Reporting
Shares (Excl. Options)
Price
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / COM
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- 403783103 - GYRE THERAPEUTICS INC - COM is tracked under CUSIP 403783103.
- Latest finished 13F holder period is not available.
- Schedule 13D/13G significant owner rows are not currently available.
Change
- Holder count moved from 1 to 2 between Q3 2024 and Q4 2025.
- Reported value moved from $1,310,305 to $9,910,928.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC Evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
403783103
Latest holder period
n/a
13F holders
13D/G owners
0
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 403783103:
Institutional Holders of GYRE THERAPEUTICS INC - COM across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 1,403,814 | $9,910,928 | +$503,745 | $7.06 | 2 |
| 2024 Q3 | 104,490 | $1,310,305 | +$105,487 | $12.54 | 1 |
| 2024 Q2 | 595,567 | $7,105,114 | +$4,571,897 | $11.93 | 2 |
| 2024 Q1 | 212,340 | $3,711,703 | +$276,971 | $17.48 | 2 |
| 2023 Q4 | 196,495 | $5,047,956 | $25.69 | 2 |